Evolva Fact Sheet

Evolva Fact Sheet
Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for
health, wellness and nutrition. Evolva’s products include stevia, vanilla, saffron and resveratrol. As well as
developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them
with a competitive edge and sharing in the returns they make.
Evolva is listed on the Swiss Stock Exchange (ticker EVE) and has operations near Basel (Switzerland), in
Chennai (India), Copenhagen (Denmark) and in the USA.
Technology platform
Evolva uses sophisticated biosynthetic and evolutionary
technologies to create and optimise small molecule
compounds and their production routes. Evolva’s
technological approach is protected by a broad IP
estate and includes multiple pending and granted
patent families.
For food and consumer health products this
capability is mainly used to establish fermentation
production routes for already used ingredients. The
focus is on ingredients where existing methods are
insufficient (they are too expensive, too variable,
too impure, too limited in scale, not sustainable,
For pharmaceutical products the capability is
mainly used to discover novel, functional
compounds the production of which may then take
place via chemical synthesis or fermentation.
Questions about our fermentation approach? Have a
look at our video
Evolva is establishing multiple discovery and codevelopment collaborations with industry partners to
develop new compounds and production methods in
the pharma, healthcare and nutrition industries.
We aim to partner our technologies and product
pipeline with companies who have the resources and
skills to conduct late stage product development and
marketing. We adopt a business-to-business model
where we share in the value of these products through
a mixture of milestone, royalty and supply agreements
with these partner companies.
Cambridge 
Evolva is led by a strong management team
with a proven track record developing and
leading biotechnology companies,
supplemented with extensive pharma
 Neil Goldsmith, Managing Director &
CEO, Co-founder. 24 year track record in
building successful biotech companies
from start-up.
 Jakob Dynnes Hansen, Chief Financial
Officer, Extensive experience in biotech
and finance. Previously with Nuevolution,
Zealand Pharma and Novo Nordisk.
 Luc Gruner, Chief Sales & Marketing
Officer, broad background in sales/
marketing, strategic planning and
business development.
 Jørgen Hansen, Chief Scientific Officer,
Previously Head of Research at Evolva
Denmark. Gathered broad experience in
yeast genetics at Poalis and Carlsberg
 Pascal Longchamp, Chief Business
Officer, Over 15 year in biotech/pharma.
Previously at Phyllom and Maxygen.
 Panchapagesa Murali, Managing
Director, Evolva India. Over 20 years in
Pharmaceutical & Healthcare R&D,
managed more than 10 clinical trials.
 Simon Waddington, CEO of Evolva
Nutrition, Inc. Has extensive experience
in venture capital as well as in
biotechnology, among others at
Monsanto and Zeneca.
Chennai  Copenhagen 
San Francisco
Product pipeline
2014 to date
Marketed by IFF
Commercial production.
Pre-launch activities
Milestone payment.
RebM patent published
Pathway optimisation.
Sensory work
> 2017
Partnership in Malaysia.
Pathway creation
Evolva’s resveratrol is a compound that has been
shown to have beneficial effects against several
health conditions related to ageing. It has selfaffirmed GRAS (Generally Regarded As Safe)
status in the USA and Novel Foods authorisation
in the EU for use in Dietary Supplements.
In the Vanillin project, Evolva is working with USbased International Flavors & Fragrances (IFF).
Commercial batches have been produced and IFF
has started the launch process by presenting the
material to flavorists and application teams.
Evolva is working with US-based Cargill on a
fermentation-based route to produce the steviol
glycoside components of the natural sweetener
Stevia. This process should allow production of
pure Stevia sweetness components with
compelling health, taste and other benefits.
Saffron is the world’s most expensive spice, as well as one of the oldest. It comes from the stigma of the
Saffron crocus and is used for food colouring and flavouring, as well as for its aroma properties. Evolva is
optimising the production process in order to enable commercial production of the saffron components.
The acquisition of Allylix in December 2014 further broadened Evolva’s pipeline.
Evolva has collaboration agreements with:
 IFF, a leading creator and manufacturer of flavours and fragrances for consumer products. Evolva works
with IFF on the vanillin project, described above.
 Cargill, a major international provider of food, agricultural and other products with 2013 revenues of
USD 137 billion. Evolva and Cargill work together in the stevia project.
 BASF, the world’s leading chemical company, to find biosynthetic routes for selected natural products
with crop protection potential.
 Roquette, a world leader in the area of nutrition and other products based on raw vegetable materials,
to find new biosynthetic production routes for an important food ingredient.
 Ajinomoto, a global manufacturer of seasonings, processed foods, beverages, amino acids,
pharmaceuticals and specialty chemicals. The project involves a natural ingredient for use in personal
care products.
 L’Oréal, widely recognised as a global leader and innovator in cosmetics, to develop novel biosynthetic
production routes for an ingredient with broad applications in the cosmetics industry.
 Takasago, a world leader in the flavour & fragrance industry, to develop biosynthetic production routes
to several ingredients with broad application in the F&F industry.
Apart from the projects in consumer healthcare and nutrition, listed above, Evolva has worked on several
pharma programmes (EV-077 and EV-035) which have been outlicensed. In addition, Evolva is active in
several research projects funded by national or EU institutions.
Evolva reported revenues of CHF 8.7m in 2013 (FY2012: CHF 7m). Cash per the end of June 2014 was CHF
61 million.
For further information on Evolva and its activities, please visit www.evolva.com.
Evolva Factsheet January 2015